

Journal Pre-proof

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline[†]

C. Sessa, J. Balmaña, S.L. Bober, M.J. Cardoso, N. Colombo, G. Curigliano, S.M. Domchek, D.G. Evans, D. Fischerova, N. Harbeck, C. Kuhl, B. Lemley, E. Levy-Lahad, M. Lambertini, J.A. Ledermann, S. Loibl, K.-A. Phillips, Paluch Shimon, on behalf of the ESMO Guidelines Committee

PII: S0923-7534(22)04193-X

DOI: <https://doi.org/10.1016/j.annonc.2022.10.004>

Reference: ANNONC 1115

To appear in: *Annals of Oncology*

Received Date: 11 July 2022


Revised Date: 5 October 2022

Accepted Date: 6 October 2022

Please cite this article as: Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P, on behalf of the ESMO Guidelines Committee, Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline[†], *Annals of Oncology* (2022), doi: <https://doi.org/10.1016/j.annonc.2022.10.004>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.



Haller 0827R1

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline[†]

C. Sessa¹, J. Balmaña², S.L. Bober³, M.J. Cardoso⁴, N. Colombo^{5,6}, G. Curigliano^{7,8}, S.M. Domchek⁹, D.G. Evans^{10,11}, D. Fischerova¹², N. Harbeck¹³, C. Kuhl¹⁴, B. Lemley¹⁵, E. Levy-Lahad¹⁶, M. Lambertini^{17,18}, J.A. Ledermann¹⁹, S. Loibl²⁰, K.-A. Phillips²¹ & Paluch-Shimon²², on behalf of the ESMO Guidelines Committee*

¹Medical Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland;

²Medical Oncology Hospital Vall d'Hebron and Hereditary Cancer Genetics Group, Vall d'Hebron Institut of Oncology, Barcelona, Spain;

³Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute/Harvard Medical School, Boston MA, USA;

⁴Champalimaud Foundation, Breast Unit and Faculdade de Medicina, Lisbon, Portugal;

⁵Department of Gynecologic Oncology, Istituto Europeo di Oncologia e IRCCS, Milan;

⁶Department of Medicine and Surgery, University of Milano-Bicocca, Milan;

⁷Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, IRCCS, Milan;

⁸Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy;

⁹Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia PA, USA;

¹⁰Manchester Centre for Genomic Medicine, Division of Evolution Infection and Genomic Sciences, University of Manchester, MAHSC, Manchester;

¹¹Manchester Centre for Genomic Medicine, MAHSC, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK;

¹²Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic;

¹³Breast Center, Department of Obstetrics & Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany;

¹⁴Department of Diagnostic and Interventional Radiology, University Hospital Aachen, University Hospital Aachen (UKA), RWTH Aachen, Germany

¹⁵KIU – Patient Organisation for Women with Gynaecological Cancer, Denmark, Clinical Trials Project, ESGO ENGAGE, Prague, Czech Republic;

¹⁶Medical Genetics Institute, Shaare Zedek Medical Center; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel;

¹⁷Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova;

¹⁸Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy;

¹⁹UCL Cancer Institute, University College London, and Department of Oncology UCL Hospitals, London, UK;

²⁰GBG Forschungs GmbH, Neu-Isenburg, Germany;

²¹Department of Medical Oncology, Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia;

²²Sharett Institute of Oncology Department, Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel.

* *Correspondence to:* ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, CH-6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org

†Approved by the ESMO Guidelines Committee: August 2016, last update October 2022. This publication supersedes the previously published version—Ann Oncol 2016; 27(Suppl 5):v103-v110.

Running header: ESMO Clinical Practice Guidelines for risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes

Word count: 10,014 (excluding title page, acknowledgements, funding and disclosure sections; tables are counted as 150 words); References: 120; Tables: 1; Figures: 2; Supplementary material: 1 (including 2 tables).

Key words:

Risk-reduction, hereditary breast & ovarian cancer syndromes, BRCA, ESMO Clinical Practice Guideline

Highlights (online only):

- This guideline provides recommendations for risk-reduction and screening for individuals with a hereditary breast and ovarian cancer syndrome.
- This guideline focuses on risk-reduction and screening mainly in unaffected carriers and particularly in high-resource settings.
- The panel encompasses an international multidisciplinary group of experts.
- Recommendations are based on available scientific data and the authors' collective expert opinion.

INCIDENCE AND EPIDEMIOLOGY

Hereditary breast and ovarian cancer syndrome (HBOC) is clinically defined by family history criteria, and molecularly defined by identification of germline pathogenic variants (PVs) in clinically validated HBOC genes.¹ These genes are broadly classified as high-risk genes, increasing breast and/or tubo-ovarian cancer risk by at least fourfold, and moderate-risk genes, increasing risk by two- to fourfold (Table 1). There is a large overlap between clinical and molecular HBOC, i.e. individuals with both family history and a PV. However, the genetic basis of about half of clinical HBOC is currently unknown, or unexplained by single-gene variants,² and conversely, approximately half of individuals who harbor PVs in HBOC genes do not have a suggestive family history.³

Studies of the prevalence of clinical and molecular HBOC are largely based on high-risk genes in individuals of Caucasian/European ancestry, whereas population-level data in unaffected persons is limited. Clinically, HBOC has been estimated to underlie ~10% of breast cancers. Molecularly, ~6% of breast cancer patients harbor PVs in HBOC genes: about half (~3%) in *BRCA1*, *BRCA2* and other high-risk genes (e.g. *PALB2*), and half (~3%) in moderate-risk genes (e.g. *ATM*, *CHEK2*).^{4,5} The remaining 4% are yet unidentified factors that may be genetic, environmental or a combination of both. In patients with high-grade ovarian cancer, germline PVs are identified in ~15% of cases.⁶

Based on objectively determined genealogy and cancer incidence data, ~12% of unaffected individuals have family history fulfilling the National Comprehensive Cancer Network (NCCN) testing criteria,⁷ a rough surrogate for clinical HBOC. The prevalence of molecular HBOC in unaffected individuals varies based on family history and ethnicity. Family history is incorporated in tools to predict the probability of harboring a hereditary PV^{8,9}—some populations harbor founder PVs with high carrier frequencies, e.g. 2.5% (1:40) for the three *BRCA1* and *BRCA2* founder PVs in Ashkenazi Jews,¹⁰ and 0.7%-0.8% (1:125-140) for the *BRCA2* founder PV in Iceland.¹¹ Studies performed in non-founder populations, largely of individuals with Caucasian/European ancestry, suggest that the carrier frequency for high-risk genes (i.e. *BRCA1*, *BRCA2*, *PALB2*) is approximately 1:150,¹²⁻¹⁴ which is consistent with early epidemiological estimates and is discussed further in Section 1 of the Supplementary Material.

Recommendations

- Individuals with significant family history should be offered genetic testing using multi-gene panels of clinically validated HBOC genes [A].
- Clinicians should be aware that family history-based testing misses about half of HBOC syndrome gene carriers, and strategies to identify these high-risk individuals are being developed [A].

POST-TEST COUNSELLING AND FOLLOW-UP OF INDIVIDUALS WITH HBOC

Genetic counselling

Once HBOC syndrome is identified, genetic counselling should address the medical and potential psychological implications for both individuals and their families. Medical implications include impact on treatment of any current cancer, and interventions for prevention or early detection of future cancers. Discussion of risks should include the risks for specific types of cancers compared with the population risks.¹⁵ As much as possible, risk assessment should be comprehensive and tailored, incorporating not only the specific gene and variant identified, but also other individual risk factors, both non-genetic (e.g. age, reproductive history) and genetic.¹⁶ Available, validated online tools that can aid in this evaluation include CanRisk (<https://www.canrisk.org/>). Risk-reduction and screening recommendations should be evidence-based where available, and include discussion of personal circumstances and preferences (e.g. family history, family planning and reproductive options).¹⁷ Counselling must include clear explanations of familial implications, indicating which relatives, both female and male, need to be informed and offered counselling and testing, in addition to counselling on reproductive implications and options [e.g. pregestational testing (PGT)]. Currently, testing is recommended only in adult relatives (except for *TP53*), although this is an evolving topic.^{17,18} The age of testing of adults can be based on legal adulthood (18 years in most countries) or on the age of potential medical actionability of the PV, which is from

approximately age 25. Timing of testing should be tailored to family history, patient preference and if PGT is being considered. Strategies that improve familial testing, including allowing direct communication by the medical team, should be sought.

Follow-up

Follow-up is a lifelong endeavor for individuals with HBOC, who manage complex schedules of serial imaging, risk-reducing surgeries (RRSs), risk-reducing medications (RRMeds) and ensuing quality of life (QoL) issues. This is best undertaken in specialized, multidisciplinary high-risk clinics including imaging services, gynecologists, breast and plastic surgeons, genetic counsellors, psychologists and linked oncologists. Such clinics have several advantages: (i) Clinical expertise in the high-risk setting, including access to clinical trials; (ii) Continuity of care, including updating risk assessment and recommendations based on new evidence; (iii) Consistency of care – ensuring that patients do not receive conflicting recommendations; and (iv) A biopsychosocial approach that provides emotional as well as medical support.

Recommendations

- Post-test genetic counselling should include discussion of medical and psychological implications, for both the individual and the family [A].
- Risk management should be individualized and, when available, validated tools should be used to aid decision making [B].
- Risk management should be performed in specialized high-risk clinics that are multidisciplinary and include psychologists where possible [A].
- Enhancing awareness and availability of testing in at-risk relatives should be a priority [A].

BREAST CANCER RISK MANAGEMENT

Imaging screening for women with high-risk PVs (BRCA1, BRCA2, PALB2)

In the presence of a PV in *BRCA1*, *BRCA2* or *PALB2*, screening should commence 5 years before the youngest affected family member, or latest at age 30. Clinical breast examination is of no value as a screening tool.¹⁹ Young age is associated with a higher breast density, which interferes with mammographic detection of breast cancer.²⁰

Magnetic resonance imaging (MRI) has consistently demonstrated improved early diagnosis of cancer compared with digital mammography and/or ultrasound in women with or without causative PVs.^{22,23} Breast cancer among women with *BRCA1* PVs exhibits fast growth rates more often than sporadic breast cancer. This shortens the 'lead time', i.e. the time available to detect the cancer while it is still in a subclinical phase, and explains the need for closer screening intervals, particularly for *BRCA1* carriers. In fact, for carriers of a *BRCA1* PV, 6-monthly screening is recommended.²¹ For *BRCA1* carriers, there appears to be little benefit of additional mammographic screening, irrespective of age; however, in *BRCA2* carriers, there may be some added benefit, with no data on *PALB2*.²⁵⁻²⁸ While 6-monthly MRI would be the optimal strategy for *BRCA1* PV carriers,²¹ in most countries, 6-monthly screening MRI is not available; thus, annual MRI may be supplemented (in between the annual MRIs) by ultrasound or mammography depending on age, availability and local guidelines.

There is no data on a cessation date of MRI for screening. Current guidelines recommend continuing MRI for as long as the woman is in good health.²⁴ Of note, it is not only breast density that drives the lower sensitivity of other breast imaging modalities in PV carriers. Accordingly, it is not recommended to 'switch' to mammography screening once density decreases with increasing age.

Retrospective studies demonstrate that 'intensified screening' results in earlier breast cancer diagnosis and improved outcomes.²⁹ 'Intensified screening' is defined as screening beyond the level recommended for individuals at average risk. It includes (i) the recommended age of screening onset, (ii) the recommended screening intervals and (iii) the methods involved for screening, as outlined in the summary recommendations below. 'Intensified screening' is also cost-effective.³⁰ Risk-reducing mastectomy results in a remaining breast cancer risk lower than that of average risk women with natural breasts. Routine intensified screening is not indicated following risk-reducing mastectomy (RRM); however, a baseline MRI in the first year after RRM to

evaluate amount of residual breast tissue is reasonable and further decisions on whether any imaging screening is mandated should be made on a case-by-case basis. While there is no available evidence on adopting this approach, it is suggested in order to compensate for the variable surgical styles with which skin-sparing and nipple-sparing risk-reducing mastectomy is carried out. Of note, there are no validated tools for measuring and quantifying residual breast tissue or for defining the amount of residual tissue that justifies or requires continued surveillance – this is an important area for research.

In women with ovarian cancer (including early and advanced stages at diagnosis) in a prolonged remission, intensified breast screening should be considered. Based on data from maintenance poly (ADP-ribose) polymerase (PARP) inhibitor trials in this population, it is reasonable to consider a ‘prolonged remission’ as being free from recurrence for at least 3 years from diagnosis.

Institutions that offer screening of HBOC families must establish the same rigorous quality assurance for MRI as done for mammography screening; clinical experience with magnetic resonance (MR)-guided vacuum-assisted biopsy must be available. There are ongoing initiatives in European and the United States to collect evidence on the long-term safety of repeated gadolinium exposure; however, to date there are no data to suggest adverse outcomes in the absence of renal insufficiency.

Recommendations:

- Women with HBOC should be offered intensified screening if they do not opt for RRM [A].
- Breast MRI should be considered the essential component of intensified screening programs [A].
- In the presence of a *BRCA1*, *BRCA2* or *PALB2* PV intensified screening should start at age 30, or 5 years younger than the youngest family member with breast cancer [A].

- There is currently no evidence on the appropriate end date of intensified screening; it is suggested to base the decision on individual factors such as breast density, comorbidities and the patient's priorities [C].
- Annual screening intervals are recommended, except for *BRCA1*, where 6-monthly screening should be considered [A].
- If half-yearly screening is considered, this may be best achieved by annual MRI and, depending on availability, resources and local guidelines, the following imaging may be considered in between annual MRI studies:
 - in carriers 30-39 years of age, ultrasound with or without mammography [C]
 - in carriers ≥ 40 years of age, mammography with or without ultrasound [C].
- There is no evidence to support continued routine breast imaging after RRM [D]. However, a baseline MRI in the first year after RRM to evaluate amount of residual breast tissue is reasonable and further decisions on imaging screening should be made accordingly on a case-by-case basis [C].
- Women in follow-up after breast-conserving treatment or unilateral mastectomy for non-metastatic hereditary breast cancer should continue with intensified screening [A].
- In women with ovarian cancer (including early and advanced stages at diagnosis) with no evidence of recurrence in a prolonged remission, intensified breast screening should be considered [C].
- There should be rigorous quality assurance of intensified screening programs, including benchmarking of program sensitivity, false-positive rate and recall rates and availability of MR-guided biopsy [A].

Lifestyle factors and breast cancer risk

All studies of lifestyle factors and hereditary breast cancer risk are observational, with potential for bias and residual confounding. Many risk factors confer consistent relative risks across the risk spectrum, resulting in greater absolute increases for those with higher underlying genetic risk. Studies of *BRCA1/2* PV carriers are limited by relatively small sample sizes and selection bias, but findings are mostly consistent with those for the general population.

Physical inactivity and being overweight postmenopausally are associated with increased breast cancer risk in those at increased familial risk.^{31,32} Breastfeeding is associated with reduced breast cancer risk for *BRCA1* PV carriers, but less so for *BRCA2*,^{33,34} which is consistent with studies in the general population demonstrating a stronger inverse association for estrogen receptor-negative disease. Conversely, the inverse associations with breast cancer risk seen in the general population for earlier age at first birth and higher parity are less clear for *BRCA1/2* PV carriers.^{33,34} Current use of hormonal contraceptives and combined hormone replacement therapy (HRT) is associated with increased breast cancer risk in the general population;^{35,36} but whether this holds true for *BRCA1/2* PV carriers is less clear.^{34,37,38} Although alcohol is associated with increased risk for breast cancer in the general population,³⁹ studies have not demonstrated a clear association for *BRCA1/2* PV carriers.^{34,40}

Recommendations:

- Physical exercise most days at moderate or strenuous intensity should be encouraged if appropriate (more is better), avoid being overweight or obese and encourage breastfeeding [B].
- Minimize alcohol intake [C].
- Decisions about hormonal contraception should weigh the possible increase in breast cancer risk against contraceptive efficacy, convenience and reduction in risk of ovarian cancer [C].

Risk-reducing medication

RRMed is an option for women who postpone, or do not undergo, elective bilateral risk-reducing mastectomy (BRRM). In randomized placebo-controlled trials for women with elevated lifetime risk of breast cancer (genetic status was only available on a very small subset of these women), the selective estrogen receptor modulators, tamoxifen and raloxifene, and the aromatase inhibitors, anastrozole and exemestane, reduce breast cancer incidence by about 30%-60%, especially estrogen receptor-positive disease. The absolute risk of serious side-effects is low, particularly for premenopausal women.⁴¹ Five years of daily tamoxifen (20 mg) or anastrozole (1 mg) reduces risk for at least 20 and 10 years, respectively. Lower dose, shorter-duration tamoxifen is an option if the 20 mg dose is not tolerated. Tamoxifen is the only option for premenopausal women. Side-effect profiles should be considered when choosing between agents for postmenopausal women, including risks of thrombosis, endometrial cancer and osteoporosis.

Data pertaining specifically to women with PVs in germline predisposition genes are extremely limited. The underpowered LIBER trial showed no reduction in first breast cancers in carriers of *BRCA1/2* PVs randomized to letrozole versus placebo.⁴² A subgroup analysis of the effect of tamoxifen for individuals with *BRCA1* and *BRCA2* in the NSABP-P1 trial was too small and thus uninterpretable.⁴³ Observational studies of tamoxifen and aromatase inhibitors for risk reduction of contralateral breast cancer have suggested benefits for carriers of both *BRCA1* and *BRCA2* PVs.⁴⁴ There are no data pertaining to PVs in other breast cancer predisposition genes.

Recommendation:

- RRMeds can be considered for primary risk reduction of breast cancer and risk reduction of contralateral disease in women who decline BRRM, or who have a risk level that does not warrant surgery [C].

Risk-reducing surgery

BRRM is the most effective method for reducing breast cancer risk among *BRCA1/2* PV carriers.⁴⁵ High-risk carriers who may wish to consider RRM are those with PVs in other high-risk genes: *TP53*, *PTEN*, *STK11*, *CDH1* and *PALB2*. For these rare and less known PVs, RRM should be discussed after careful consideration of individualized risk assessment.⁴⁶ In all affected high-risk PV carriers, contralateral risk-reducing mastectomy (CRRM) lessens the incidence of contralateral breast cancer without proven impact on overall survival (OS).^{45,47}

BRRM reduces the risk of breast cancer by ~90% depending on the study and type of surgery performed.⁴⁵ No randomized controlled studies of this procedure have been performed. One study reported a benefit in disease-specific survival in *BRCA1* carriers, despite limitations in the control group.⁴⁸

The benefits of RRM are likely greatest if performed from the age of 30 (until the age of 30, the cumulative risk of breast cancer for *BRCA1* and *BRCA2* carriers is only 4%);⁴⁹ however, beyond age 55, the evidence for benefit is weak.⁵⁰ Ultimately, the decision regarding if and when to perform RRM is determined by patient preference and may be influenced by family history.

BRRM is an extensive procedure that needs to be carefully discussed taking into consideration benefits, complications and psychosocial impact.⁵¹ A variety of techniques exist: ranging from total mastectomy (TM), to skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM), which aim to improve cosmetic results. Limited data suggest NSM provides similar risk reduction and possibly superior cosmetic outcomes than TM or SSM; however, follow-up is limited.⁵² Immediate breast reconstruction should be offered.

Recommendations

- BRRM is the most effective method for reducing breast cancer risk for *BRCA1/2* carriers and should be discussed in the context of individually tailored decision making [B].

- BRRM should be discussed in carriers of other high-risk genes alongside family history – *TP53*, *PTEN*, *STK11*, *CDH1* and *PALB2* [C].
- NSM is a reasonable alternative to TM [C].
- Immediate reconstruction is safe and should be offered [C].
- In women with stage I-III high-risk PV-associated breast cancer (not including *TP53*), breast-conservation with therapeutic radiation is a safe alternative to RRM. RRM should be considered within the context of disease prognosis, risks and benefits and patient preference [C].
- In women with ovarian cancer (including early and advanced stages at diagnosis) in a prolonged remission, RRM may be considered on a case-by case basis [C].

OVARIAN CANCER RISK MANAGEMENT

Imaging and screening

All studies of ovarian and fallopian tube cancer screening in HBOC carriers are observational. Potential benefits of screening based on transvaginal ultrasound and a cancer antigen 125 (CA-125) test include disease downstaging and higher rates of complete resection with lower surgical complexity.^{53,54} However, it remains unknown whether screening improves survival in high-risk women (see Section 2 of the Supplementary material). False positive results may lead to unnecessary surgery, of particular concern in women below the age at which risk-reducing bilateral salpingo-oophorectomy (RRBSO) is recommended or those who have not completed childbearing.^{53,54} An experienced sonographer (Level 3 practitioner) can distinguish between benign and malignant ovarian tumours to avoid unnecessary surgeries.⁵⁵ Identifying specific histological subtypes, such as high-grade serous cancer, which is the most frequently represented cancer among *BRCA1/2* PV carriers, is desirable.⁵⁶

There are no data to support ongoing gynecological screening after RRBSO.

Recommendations

- Although of uncertain benefit, ovarian screening with transvaginal ultrasound every 6 months and serum CA-125 determination may be considered starting at the age at which RRBSO is offered (and until RRBSO is performed). Clear benefits of RRBSO alongside the limitations and harms of screening should be communicated to patients [C].
- Screening, if performed, should be provided in tertiary care/high-volume centers under structured screening protocols by an experienced sonographer [C].
- There is no evidence to support routine screening after RRBSO [D].

Lifestyle factors & risk-reducing medication

Use of the oral contraceptive pill (OCP) is associated with 40%-60% lower risk for ovarian cancer.³⁴ However, as noted earlier, there are conflicting data on whether OCP increases breast cancer risk amongst *BRCA1/2* carriers.^{34,37} The long-term clinical significance of OCP use as a risk-reduction measure for ovarian cancer is unclear, given that PV carriers are encouraged to undergo RRBSO before the age at which ovarian cancer risk becomes relevant.

Risk-reducing surgery

Considering the absence of reliable screening for early detection and the poor prognosis associated with advanced ovarian cancer, the most effective approach to prevent ovarian and fallopian tube cancers is RRBSO.⁵⁷ Pathological evaluation of the surgical specimen should include a Sectioning and Extensively Examining the Fimbriated End (SEE-FIM) protocol.

RRBSO should include bilateral removal of both ovaries and fallopian tubes and should be reserved for patients at high risk of epithelial ovarian and fallopian tube cancer; it is commonly recommended for patients with PVs in *BRCA1/2*, *BRIP1*, *RAD51C*, *RAD51D*

or the Lynch syndrome genes *MLH1*, *MSH2* and *MSH6*. RRBSO may be considered for postmenopausal women with a *PALB2* PV.

In women with a PV in *BRCA1/2*, RRBSO has been shown to be effective in reducing the risk of gynecological tumours (including ovarian, fallopian tube or primary peritoneal cancers) by 80%-90%, and to decrease the all-cause mortality by 77%.⁵⁸

There is debate about whether RRBSO also significantly reduces the risk of breast cancer, particularly for premenopausal *BRCA1* carriers. Based on current evidence, this surgical procedure is not recommended specifically to decrease the risk of breast cancer.^{58,59}

The PV type, patient's preferences and family history should be taken into consideration when deciding the timing of RRBSO. It should be delayed until an age when ovarian cancer risk is increased above that of the general population. Performing RRBSO before the necessary age can have a negative impact on a woman's health including all the consequences of premature menopause (increased risk of osteoporosis, cognitive dysfunction, cardiovascular disease and early mortality) – thus appropriate timing is critical.

The average age of ovarian cancer diagnosis varies with type of PV, and in patients with *BRCA2* PVs is an average of 8-10 years later than in women carriers of *BRCA1* PVs. For this reason, RRBSO is recommended once the desire for pregnancy is completed in women aged between 35 and 40 years who carry *BRCA1* PVs, and in women aged between 40 and 45 years with *BRCA2* PVs.⁶⁰ Of note, for women with a *BRCA2* PV, in the absence of family history of early onset ovarian cancer, it is reasonable to perform RRBSO at 45 years of age.

The most appropriate approach to RRS is through minimally invasive surgery with laparoscopic route to reduce morbidity and hospitalisation time and provide a better aesthetic outcome.

The use of salpingectomy with delayed oophorectomy is under investigation as a strategy in *BRCA1* and *BRCA2* PV carriers in several prospective observational trials such as WISP, PROTECTOR, SOROCK and TUBA.⁶¹⁻⁶⁴ Given the strong evidence that

RRBSO leads to a reduction in mortality, the prospective studies detailed above are necessary prior to wide implementation of salpingectomy with interval oophorectomy, particularly for *BRCA1* carriers with an earlier onset and higher risk of ovarian cancer.

There are conflicting data on the risk of developing endometrial cancer in patients with *BRCA* PVs. Some studies suggest a connection between *BRCA* PVs and development of serous uterine cancer (primarily in *BRCA1*) with a two- to threefold increased risk and yet a more recent study does not demonstrate any elevated risk.⁶⁵ In any case, any absolute risk remains low, and it is not clear if the potential magnitude of benefit associated with hysterectomy is sufficient to justify the risks associated with the procedure.⁶⁶⁻⁶⁸

Hysterectomy should not be routinely recommended at the time of RRBSO to reduce cancer risk, unless other indications for this procedure exist, such as a PV in the *MLH1*, *MSH2* or *MSH6* genes, other risk factors for endometrial cancer or benign uterine pathology. Current data support a lower risk of endometrial and ovarian cancer in *PMS2* mutation carriers, with insufficient evidence to recommend prophylactic surgery.^{69,70} (For further information on management of Lynch syndrome, please refer to <https://www.esmo.org/guidelines/guidelines-by-topic/gastrointestinal-cancers/hereditary-gastrointestinal-cancers>).

Some carriers may choose to undergo hysterectomy with RRBSO to use estrogen-only HRT, which is associated with a decreased risk of breast cancer, without increasing their risk of endometrial cancer.⁷¹

Recommendations

- The most effective strategy for ovarian cancer risk reduction in *BRCA1/2* PV carriers is RRBSO [A].
- RRBSO should be carried out in women who have completed childbearing, at age 35-40 for *BRCA1* PV carriers and at age 40-45 for women with *BRCA2* PVs. Timing of surgery should take into consideration family history [B].

- RRBSO should be considered in women who have completed childbearing who are carriers of PVs in *BRIP1*, *RAD51C*, *RAD51D* at age 45-50. RRBSO may be considered for postmenopausal women with a *PALB2* PV [C]. For gynecological risk-reducing surgery in Lynch syndrome, please refer to <https://www.esmo.org/guidelines/guidelines-by-topic/gastrointestinal-cancers/hereditary-gastrointestinal-cancers>.
- Risk-reducing salpingectomy (bilateral salpingectomy alone or bilateral salpingectomy followed by delayed oophorectomy) are not recommended outside the setting of a clinical trial [C].

RISK-REDUCTION & SCREENING OF OTHER *BRCA*-ASSOCIATED CANCERS & APPROACH TO MALE CARRIERS

Male carriers – breast cancer

Cancer risks specific to men include male breast and prostate cancer. The lifetime risk (LTR) of male breast cancer in the general European population is ~0.1% and prostate cancer 10%-12.5%. There is evidence for an increased risk of male breast cancer for nearly all HBOC genes.⁷²⁻⁷⁵ The most compelling is for men with *BRCA2* PVs, with LTR of up to 8%.⁷³ For other genes, LTR is <1%. Risks can be substantially increased by the presence of gynecomastia [relative risk (RR) 9.8] or Klinefelter syndrome (RR 24.7).⁷⁶ There is little evidence of efficacy of routine mammography screening in males.

Male carriers – prostate cancer

The HBOC genes have been widely linked with an increased risk of prostate cancer. The evidence for a significantly increased risk is more robust for *BRCA2*,^{77,78} while several studies do not demonstrate an elevated risk for *BRCA1*.⁶⁵ There is a moderately increased risk for *ATM*^{79,80} but inconsistent evidence to confirm an increased risk with *PALB2*⁷⁵ or *CHEK2*.⁸¹ The evidence for prostate cancer screening is largely based on the IMPACT screening study. *BRCA2* carriers had a higher incidence than *BRCA2* non-carriers and were diagnosed significantly younger and with more aggressive disease.⁸²

Using a prostate-specific antigen (PSA) threshold of 3.0 ng/ml, tumors were detected at a more treatable early stage and prostate cancer screening was recommended for *BRCA2* carriers.

Recommendations

- Annual mammography or ultrasound screening should be considered in male *BRCA2* carriers with additional high-risk features such as gynecomastia or Klinefelter syndrome from age 50 or 10 years before earliest male breast cancer in the family [C].
- Male *BRCA2* carriers should be encouraged to be aware of physical changes in the breast and seek medical attention accordingly [C].
- Annual blood PSA screening should be offered to male *BRCA2* carriers from age 40 years [B] and may be considered for male *ATM* carriers from age 40 years [C].

Pancreatic cancer screening

Several guidelines make recommendations on pancreatic cancer screening⁸³⁻⁸⁶ based on evidence from studies that included individuals with PVs in genes associated with pancreatic cancer and/or those who have strong familial pancreatic cancer risk (at least two first-degree relatives on the same side of the family). However, most evidence has been garnered in genetic conditions with higher pancreatic cancer risks than in *BRCA1*, *BRCA2*, *ATM* or *PALB2*,⁸⁶⁻⁸⁹ such as *STK11* and *CDKN2A* (Supplementary Table S1). Some suggest offering screening from age 50 in HBOC carriers with a close relative, defined as a first- or second-degree relative with pancreatic cancer. While current studies suggest that surveillance can achieve 'downstaging' at diagnosis, advanced interval cancers are common, and there is no evidence for improved survival. Notably, in one recently published screening study for patients considered at high risk for

developing pancreatic cancer, the majority of screening-detected pancreatic cancers were stage I with favourable long-term outcomes.⁹⁰

Recommendations

- Screening with annual contrast enhanced MRI and/or endoscopic ultrasound from age 35 (or 5-10 years younger than affected relative) may be considered in *STK11* carriers [C].
- Screening (as above) from age 50 (or 5-10 years younger than affected relative) may be considered in *BRCA1*, *BRCA2*, *ATM*, *TP53* or *PALB2* carriers with at least one first- or second-degree relative with exocrine pancreatic cancer [C].
- Screening should be performed in a center with high volume experience [C].
- All screening should ideally be carried out as part of a clinical trial [A].

COUNSELLING, RISK-REDUCTION AND SCREENING IN THE PRESENCE OF OTHER MODERATE-HIGH RISK GENETIC PV HBOCS

Genetic testing for HBOC susceptibility often incorporates screening for PVs in genes beyond *BRCA1* and *BRCA2*. Many of these genes are involved in the homologous DNA repair pathway; however, associated cancer risks (in terms of types of cancer and their LTRs) vary widely gene by gene (Table 1) as do the approaches to screening and risk reduction. During counselling, it is important to differentiate ‘other genes’ from *BRCA1* and *BRCA2*.

PVs in *PALB2*, *CDH1*, *PTEN*, *STK11* and *TP53* are associated with a high LTR for breast cancer. The latter four are associated with specific syndromes [Hereditary Diffuse Gastric Cancer (*CDH1*), Cowden (*PTEN*), Peutz-Jeghers (*STK11*) and Li Fraumeni syndromes (*TP53*)] with associated guidelines.^{15,18,91-93} Annual MRI screening is recommended from age 20 for *TP53* and from age 30 for *PALB2*, *CDH1*, *PTEN* and *STK11*, tailored to family history. BRRM may be discussed on a case-by-case basis.

PVs in *PALB2* are associated with breast cancer risk of 40%-60%;⁷⁵ (approach to screening and RRS described above).^{15,85,94} PVs in *ATM* and truncating PVs in *CHEK2* are associated with LTR of breast cancer of ~25%, although these risks are modified by family history, mammographic breast density and single nucleotide polymorphisms (SNPs) in the context of a polygenic risk score (PRS).⁹⁵ Although the United States NCCN guidelines recommend enhanced screening solely on the basis of an *ATM* or truncating *CHEK2* PV,¹⁵ the authors advise that screening recommendations consider integration of these risk factors and the addition of MRI to mammographic screening from age 40. The data regarding *BARD1*, *RAD51C* and *RAD51D* are complicated as they are associated with an increased risk of triple-negative breast cancer, without substantially increasing overall risk of breast cancer (RR ~2).^{4,5} Screening recommendations need to consider known risk factors including family history and mammographic density.

The LTR of associated ovarian cancer varies widely (Table 1). PVs in *BRIP1*, *RAD51C* and *RAD51D* are associated with risks of $\geq 10\%$, thus RRBSO is recommended by age 45-50.¹⁵ The risk of ovarian cancer in *PALB2* is 3%-5% and that of *ATM* likely $\leq 5\%$. Premenopausal RRBSO is not routinely recommended at this level of risk. In postmenopausal women with *PALB2* PV, RRBSO can be considered. *CHEK2* PVs are not associated with ovarian cancer risk.⁹⁶ Recommendations for RRBSO have been discussed previously in this manuscript. Conflicting data exist about elevated risk of colon cancer associated with *CHEK2* PVs.⁹⁶ Risks associated with prostate cancer and pancreatic cancer are discussed earlier.

NBN, *MRE11* and *RAD50* were not validated as breast cancer genes in two recent large international studies.^{4,5}

Recommendations

- Women with PVs in *ATM*, *BARD1*, *CHEK2* (truncating), *RAD51C* or *RAD51D* should have comprehensive assessment of breast cancer risk to determine eligibility for breast MRI [C].

- In the presence of *CDH1*, *PTEN* or *STK11* PVs, intensified breast screening should start at age 30, or 5 years younger than the youngest family member with breast cancer and from age 20 for *TP53* [A].
- RRBSO should be considered in women who have completed childbearing who are carriers of PVs in *BRIP1*, *RAD51C* and *RAD51D* at age 45-50. RRBSO may be considered for postmenopausal women with a *PALB2* PV [C]. For gynecological risk-reducing surgery in Lynch syndrome, please refer to <https://www.esmo.org/guidelines/guidelines-by-topic/gastrointestinal-cancers/hereditary-gastrointestinal-cancers>.
- Validated risk assessment tools such as CanRisk (<https://www.canrisk.org/>) may be used to aid individual risk management [C].

REPRODUCTIVE AND ENDOCRINOLOGICAL ISSUES IN INDIVIDUALS WITH HBOC

Several unique reproductive and endocrinological considerations exist for women with HBOC.

Contraception

The most used forms of contraception remain hormonally based – OCP, injectables/implants and the progesterone-intrauterine device (IUD). Reservations about use of the OCP have been addressed earlier. While not contra-indicated, unaffected carriers should be offered alternative non-hormonal forms of contraception when feasible and minimise prolonged periods of exposure to exogenous hormones. Noteworthy, in women interested in tamoxifen chemoprevention, concurrent use of the OCP is contraindicated due to elevated risk of venous thromboembolism (VTE).

Fertility

A growing body of preclinical evidence has suggested that *BRCA* function and ATM-mediated DNA double-strand break repair are implicated in ovarian aging.⁹⁷

Nevertheless, clinical evidence remains controversial.⁹⁷ Therefore, although a potential negative impact on female ovarian reserve and reproductive potential cannot be excluded, no definitive counselling can be made in this regard. In male carriers, gonadal function is apparently normal, but data are limited.⁹⁷

Completion of childbearing before the recommended age for RRBSO should be encouraged. If this is not feasible, oocyte and embryo cryopreservation can be offered at a young age, similar to cancer patient candidates for fertility preservation strategies prior to chemotherapy.⁹⁸ Albeit limited, the available safety data in this setting are reassuring, without apparent increased breast or ovarian cancer risk following ovarian stimulation for oocyte collection.⁹⁷

Carriers with highly penetrant cancer susceptibility syndromes should be informed about the possibility to access prenatal diagnosis or preimplantation genetic testing (PGT) that may be used if they would like to avoid passing on the hereditary PV to future offspring.⁹⁹ Carriers should be counselled about any relevant risk of associated autosomal recessive syndromes such as Fanconi Anaemia (may be relevant for *BRCA1/2*, *PALB2*, *BRIP1* and *ATM* PV carriers) and testing of partners. Pros and cons of these strategies, including potential pregnancy termination in the case of prenatal diagnosis and the need for *in vitro* fertilization (IVF) strategies with PGT, should be clearly discussed. Religious, cultural, ethical and socioeconomic issues, as well as country/center availability, are important factors affecting the individual's choice to access these technologies.⁹⁸ Thorough and balanced counselling putting couples' autonomy in the center of the decision-making process is key.

Management of menopausal symptoms

Healthy carriers undergoing RRBSO at a young age should be informed of short- and long-term health consequences of premature menopause.

Data on use of HRT in unaffected carriers is limited and mostly retrospective. Results from ongoing prospective studies are awaited. While some data suggest that HRT is safe, a recent study has suggested that this may be true for women up to age 45;

however, beyond that, there may be an increased risk of breast cancer.^{100,101} Thus, short-term HRT may be offered after RRBSO. Longer-term use of HRT for unaffected carriers >45 years who have also previously undergone BRRM may be considered on a case-by-case basis. Limitations and risks of HRT should be clearly communicated, and while mitigating menopausal symptoms and risk of osteoporosis, any benefits in cardiovascular and cognitive health are controversial.

In contrast to systemic HRT, local vaginal therapies, including low-dose intravaginal estrogens, may be considered to manage genitourinary symptoms of menopause, including vulvovaginal dryness and dyspareunia as well as urinary symptoms of urgency, dysuria or recurrent urinary tract infection (UTI).

Bone health

Regular assessment of clinical risk factors for accelerated bone loss and measurement of bone mineral density is recommended for women who underwent RRBSO while premenopausal.¹⁰² Resistance and weight-bearing exercise, smoking cessation and reduced alcohol intake are highly encouraged, together with vitamin D and calcium supplements and antiresorptive therapy whenever indicated.¹⁰²

Recommendations

- Healthy female carriers should be encouraged to complete childbearing before the recommended age for RRBSO [A]; if this is not feasible, oocyte and embryo cryopreservation can be offered at a young age [B].
- Patients with HBOC should be informed about the options of prenatal diagnosis or PGT [A].
- In unaffected *BRCA1/2* carriers, discussing limitations and risks, HRT after RRBSO may be considered to alleviate menopausal symptoms [C].

- Bone assessment should be considered, tailored to individual risk factors. Preventive/therapeutic measures should be considered as indicated [B].
- Low-dose intra-vaginal estrogens may be considered to manage genitourinary symptoms of menopause [C].

UNIQUE PSYCHOLOGICAL ISSUES FOR INDIVIDUALS WITH HBOC

Results of observational studies of the psychological impact of HBOC are highly variable.¹⁰³ Although it is often assumed that carriers have increased psychological distress (e.g. anxiety, depression), at least half of studies to date report no differences in distress between carriers and non-carriers.^{104,105} Moreover, increased levels of psychological distress observed in the immediate weeks following genetic testing disclosure have been shown to return to baseline levels 6-12 months later, with no significant clinically relevant symptoms in the long-term.^{106,107} There are, however, individual women who do experience elevated and sustained levels of psychological distress in this setting. Individual risk factors include high levels of anxiety and depression prior to genetic testing,¹⁰⁶ presence of a cancer diagnosis,¹⁰⁸ being unpartnered and family cancer history.¹⁰⁹ Evidence regarding the effectiveness of psychosocial interventions is emerging but limited,¹¹⁰ with most interventions focusing on delivering information and emotional support.

Observational studies consistently reveal a negative impact on sexual function, including vaginal dryness and loss of sexual satisfaction following RRBSO. Moreover, studies show that sexual dysfunction is long-lasting and that decrement in function is independent of menopausal status prior to RRBSO or use of HRT.¹¹¹ The impact of HBOC on body image has primarily been assessed in the context of BRRM. In contrast to sexual function, impact of BRRM on body image is more complex.¹¹² Although quantitative studies demonstrate that most women are satisfied with their decision to undergo RRM,¹¹³ qualitative studies reveal various negative effects, including distress about loss of sensation and discomfort with reconstructed breasts as well as decreased perceived attractiveness and femininity.¹¹⁴ Salient risk factors for decreased body image

include poor reconstruction outcomes, surgical complications and lack of information prior to surgery.¹¹⁴

Recommendations

- The need for further informational and emotional support should be assessed prior to genetic test disclosure, and individuals should be offered referrals for either psychological counselling and/or further support [B].
- Sexual health concerns should be assessed, and individuals should be offered support and resources as needed to address sexual dysfunction. Individuals should be asked about sexual health concerns regardless of age, partner status or sexual orientation [A].

PERSONALISED MEDICINE AND FUTURE DIRECTIONS

The use of germline genetic testing has led to vast improvements in screening, risk-reduction and therapies for those with inherited cancer susceptibility. Despite this, there is a need for more individualized risk assessment to inform timing and type of risk-reduction strategies, such as RRM and RRBSO. In *BRCA1* and *BRCA2* PV carriers, for example, *BRCA* genotype, family history and genetic modifiers all impact individual risk. SNPs have been well validated to alter cancer risk both in the general population and in those with inherited cancer susceptibility.¹¹⁵ A PRS captures the risk associated with SNPs and can be used in models such as CanRisk.⁹⁵ PRSs may be particularly important in individuals with inherited PVs in *ATM* or *CHEK2* as some of these individuals will have close to average risk of breast cancer and others quite elevated risk. Modification by PRS is likely to become increasingly important as individuals without a strong family history of cancer undergo genetic testing. Research is ongoing to understand how to most effectively use PRSs clinically.

Early data from the OlympiA adjuvant study of olaparib suggests a potential role for PARP inhibitors for risk-reduction.¹¹⁶ However, studies are needed to examine the risk,

benefit and schedule in healthy individuals. Denosumab and acetyl salicylic acid (aspirin) are part of ongoing risk-reduction studies to advance this area in *BRCA1/2* carriers.¹¹⁷

An early detection strategy using liquid biopsies targeting tumour-derived mutational, epigenetic or transcriptomic features is another emerging area with relevance to individuals with genetic susceptibility. Techniques which would allow early detection of cancers such as ovarian cancer and pancreatic cancer may fundamentally alter our approach. For example, if stage I ovarian cancer could be reliably detected, routine use and/or timing of RRBSO could be reconsidered. Avoiding surgery-induced menopause in women in their 30s could have a major impact on QoL and long-term outcomes on bone and cardiac health. Early data are provocative; however, these tests may not have the needed performance characteristics in early stage breast, ovarian and pancreatic cancer, and false positives are common.¹¹⁸ Thus, they are not recommended for clinical use at this time.

Recommendation:

- Use of PRSs, interval salpingectomy, novel risk-reduction strategies and liquid biopsy assays for early detection should continue to be carried out and assessed in the context of clinical trials [A].

METHODOLOGY

This Clinical Practice Guideline was developed in accordance with the European Society for Medical Oncology (ESMO) standard operating procedures for Clinical Practice Guidelines development (<http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology>). The relevant literature has been selected by the expert authors. Grades of recommendation have been applied using the system shown in Supplementary Table S2.^{119,120} Statements without grading were considered justified standard clinical practice by the authors. Level of evidence has not been provided as no randomized controlled

studies are available in this field, with most data being observational/retrospective. For future updates to this CPG, including eUpdates and Living Guidelines, please see the ESMO Guidelines website: <https://www.esmo.org/guidelines/guidelines-by-topic/hereditary-syndromes>.

ACKNOWLEDGEMENTS

DGE is supported by the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007). ML is supported by the Italian Association for Cancer Research (“Associazione Italiana per la Ricerca sul Cancro” AIRC; MFAG 2020 ID 24698). KAP is a National Health and Medical Research Council (Australia) Leadership Fellow. Manuscript editing support was provided by Fraser Simpson and Claire Bramley (ESMO Guidelines staff) and Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO.

FUNDING

No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds.

DISCLOSURE

CS has reported non-remunerated activities as Coordinator Gynecological Programme for the European School of Oncology.

JB has reported fees for advisory board membership for AstraZeneca and Pfizer; fees paid to her institute for roles as Local Principal Investigator for AstraZeneca, MedSire and Pfizer.

SLB has reported fees as an author for UpToDate. She has also reported non-remunerated activities as the Chair of The Scientific Network on Female Sexual Health and Cancer (academic organisation).

MJC has reported fees as an invited speaker for Roche (industry-sponsored symposium in National Conference). She has also reported non-remunerated activities as a member of the Board of Directors of EUSOMA, faculty member of ESO, project lead / lead investigator for the Breast Research Group of INESC TEC and President of MAMA Help (non-profit association for breast cancer patients in Portugal). She serves as a Specialty Editor for The Breast.

NC has reported fees for advisory board membership for AstraZeneca, BIOCAD, Clovis Oncology, Eisai, GSK, Immunogen, Mersana, MSD/Merck, Nuvation Bio, Onxerna, Pfizer, PharmaMar, Pieris and Roche; fees as an invited speaker for AstraZeneca, Clovis Oncology, GSK and MSD/Merck; institutional research grants from AstraZeneca, PharmaMar and Roche. She has also reported non-remunerated activities as member of the ESMO Guidelines Steering Committee and chair of the Scientific Committee of ACTO (Alleanza contro il tumore ovarico).

GC has reported fees for advisory board membership for AstraZeneca, BMS, Celcuity, Daiichi Sankyo, Ellipsis, Exact Sciences, Lilly, Merck, Pfizer, Roche and Veracyte; fees as an invited speaker for AstraZeneca, Daiichi Sankyo, Novartis, Pfizer and Roche; fees for a writing engagement from Pfizer; institutional research grant from Merck for an investigator-initiated trial; institutional funding for Phase I studies from Astellas, AstraZeneca, Blueprint Medicine, BMS, Daiichi Sankyo, Kymab, Novartis, Philogen, Relay Therapeutics, (coordinating principal investigator), Roche and Sanofi. He has also reported non-remunerated activities as an Italian National Health Council as Advisor for Ministry of Health (Consiglio Superiore di Sanità), member of the Scientific Council for the patient advocacy association Europa Donna, advisory role at the Fondazione Beretta cancer research foundation, member of the Board of Directors for Lega Italian Lotta ai Tumori (public national company for cancer prevention) and member of the Advisory Council of EUSOMA.

SMD has reported personal honoraria from AstraZeneca, BMS and Clovis; fees paid to her institute as coordinating principal investigator for AstraZeneca.

DGE has reported fees for advisory board membership for Recursion, Springworks and Syanatra; consultancy fees for a writing engagement for AstraZeneca.

DF has reported no potential conflicts of interest.

NH has reported fees for advisory board membership for Aptitude Health, AstraZeneca, Daiichi Sankyo, Gilead, Novartis, Pfizer, Roche, Sandoz-Hexal, Sanofi and SeaGen; fees as an invited speaker for Art Temp, AstraZeneca, Daiichi Sankyo, Exact Sciences, Gilead, Lilly, Medscape, MSD, Novartis, Onkowsen, Pierre Fabre, Roche, Sanofi and Seagen; institutional funding from AstraZeneca, BMS, Daiichi Sankyo, Lilly, MSD, Novartis, Palleos, Pierre Fabre, Roche, Seagen, TRIO and WSG; ownership interest in the West German Study Group. She has also reported non-remunerated activities as a member of the AGO Breast Guideline Committee and member of the ESO/ESCO Breast Cancer Educational Programs. She is the Founding Editor of the BreastCare Journal.

CK has reported fees for advisory board membership for Guerbet; fees as an invited speaker for Bayer and Bracco.

BL has reported fees received from the Rising Tide Foundation as a patient reviewer. She has also reported non-remunerated activities as a member of ESGO ENGAGE (Past Executive Board Member) and chair of KIU - Danish Patient Organisation for Women with Gynaecological Cancer.

ELL has reported employment as the Director of the Medical Genetics Institute of the Shaare Zedek Medical Center. She has also reported non-remunerated activity as the Vice-President of the Israel National Academy of Science in Medicine (non-profit).

ML has reported fees for advisory board membership and speaker fees for AstraZeneca, Exact Sciences, Gilead, Lilly, MSD, Novartis, Roche and Seagen; fees as an invited speaker for Ipsen, Knight, Libbs, Pfizer, Sandoz, Seagen and Takeda.

JAL has reported fees for advisory board membership for Artios Pharma, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Eisai, Ellipses, GSK, Immunogen, Merck/MSD, Nuvation, Pfizer and VBL Therapeutics; speaker fees from AstraZeneca, Clovis Oncology, GSK and Neopharm; fees related to an Independent Data Monitoring Committee for Regeneron; institutional research grants from AstraZeneca, Clovis Oncology, Eisai, GSK, MSD/Merck and Pfizer. He has also reported non-remunerated

activities as Vice-President of the European Society of Gynaecological Oncology (2019-2021). He serves as an Associate Editor of *Therapeutic Advances in Medical Oncology* (Sage Publishing).

SL has reported fees paid to her institute for advisory board membership for Abbvie, Amgen, AstraZeneca, BMS, Celgene, DSI, EirGenix, Gilead, GSK, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Relay Therapeutics, Roche, Sanofi and SeaGen; fees paid to her institute as an invited speaker for AstraZeneca, DSI, Gilead, Novartis, Pfizer and Roche; employment as the CEO of GBG Forschungs GmbH; licensing fees paid to her institute by VM Scope GmbH; research grants to her institute from AstraZeneca, Celgene, Daiichi-Sankyo, Immunomedics/Gilead, Novartis, Pfizer and Roche; institutional funding from Abbvie and Molecular Health; fees paid to her institute as principal investigator (Penelope/Padma) from Pfizer; fees paid to her institute from AstraZeneca (SC Capitello), Daiichi Sankyo (SC Destiny B05), Immunomedics/Gilead (SC ASCENT), Novartis (SC SOLAR1), Pfizer (SC PALOMA3), Roche (SC Inavo and SC Katherine), Seagen (SC HERCLIMB). She has also reported non-remunerated activities as principal investigator for Aphinity, advisory role to AGO Kommission Mamma (group in Germany responsible for breast cancer guidelines), membership of AGO, DKG, ASCO and ESMO including membership of the ESMO Guidelines Committee and past chair of the ESMO Breast Congress. She has reported institutional patents for which she has no financial interests: EP14153692.0, EP21152186.9, EP15702464.7, EP19808852.8.

K-AP has reported non-remunerated activities as Advisory Board member for AstraZeneca, Scientific Advisory Committee member for Breast Cancer Trials, project lead in Australia for the DECREASE and OlympiA studies, member of the Expert Advisory Group on Cancer Clusters for the Victorian Department of Health and Human Services, Strategic Advisory Committee member for Breast Cancer Network Australia, Cancer Genetics Reference Committee Member for NSW Cancer Institute; advisory role on the register of experts for breast and hereditary cancer for the Medical Oncology Group of Australia and Breast cancer optimal care pathway committee member for Cancer Council Victoria. She is also a Leadership Fellow of the National Health and

Medical Research Council (Australia) and a Practitioner Fellow of the National Breast Cancer Foundation (Australia).

SP-S has reported fees paid to her institute for advisory board membership for AstraZeneca, Eli Lilly, Exact sciences, Medison, Pfizer and Roche; fees paid to her institute as an invited speaker for AstraZeneca, Eli Lilly, Exact sciences, Medison, Novartis, Pfizer and Roche; fees paid to her institute for consultancy for Medison; personal and institutional research grant for an RFP independent research put out by SPCC and Pfizer.

Journal Pre-proof

REFERENCES

1. Lee K, Seifert BA, Shimelis H, et al. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. *Genet Med.* 2019;21(7):1497-1506.
2. Melchor L, Benitez J. The complex genetic landscape of familial breast cancer. *Hum Genet.* 2013;132(8):845-863.
3. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. *Proc Natl Acad Sci U S A.* 2014;111(39):14205-14210.
4. Breast Cancer Association C, Dorling L, Carvalho S, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *N Engl J Med.* 2021;384(5):428-439.
5. Hu C, Hart SN, Gnanaolivu R, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. *N Engl J Med.* 2021;384(5):440-451.
6. Norquist BM, Harrell MI, Brady MF, et al. Inherited Mutations in Women With Ovarian Carcinoma. *JAMA Oncol.* 2016;2(4):482-490.
7. Greenberg S, Buys SS, Edwards SL, et al. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. *Cancer Med.* 2019;8(15):6789-6798.
8. Carver T, Hartley S, Lee A, et al. CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. *Cancer Epidemiol Biomarkers Prev.* 2021;30(3):469-473.
9. Nelson HD, Pappas M, Cantor A, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2019;322(7):666-685.
10. Roa BB, Boyd AA, Volcik K, et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. *Nat Genet.* 1996;14(2):185-187.
11. Stefansdottir V, Thorolfsdottir E, Hognason HB, et al. Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland. *Eur J Hum Genet.* 2020;28(12):1656-1661.

12. Rowley SM, Mascarenhas L, Devereux L, et al. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. *Genet Med*. 2019;21(4):913-922.
13. Manickam K, Buchanan AH, Schwartz MLB, et al. Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants. *JAMA Netw Open*. 2018;1(5):e182140.
14. Maxwell KN, Domchek SM, Nathanson KL, et al. Population Frequency of Germline BRCA1/2 Mutations. *J Clin Oncol*. 2016;34(34):4183-4185.
15. Daly MB, Pal T, Berry MP, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2021;19(1):77-102.
16. Gallagher S, Hughes E, Kurian AW, et al. Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. *JCO Precis Oncol*. 2021;5.
17. Hercher L. Discouraging Elective Genetic Testing of Minors: A Norm under Siege in a New Era of Genomic Medicine. *Cold Spring Harb Perspect Med*. 2020;10(5):a036657.
18. Frebourg T, Bajalica Lagercrantz S, Oliveira C, et al. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. *Eur J Hum Genet*. 2020;28 (10):1379-1386.

Table 1. Lifetime cancer risks in HBOC-associated PVs

	Breast Cancer*	Tubo-ovarian Cancers†	Pancreatic Cancer‡	Colon Cancer§	Other Cancers
<i>ATM</i>	Yes 25%-30%	Yes <5%	Yes <5%	No	Prostate 30%
<i>BARD1</i>	Yes ~20%	No	No	No	No
<i>BRCA1</i>	Yes >60%	Yes 40%-60%	Yes <5%	No	
<i>BRCA2</i>	Yes >60%	Yes 15%-30%	Yes <5%	No	Prostate 33%
<i>BRIP1</i>	No	Yes 5%-10%	No	No	No
<i>CDH1</i>	Yes (LBC) 40%	No	No	No	Diffuse gastric cancer 35%-45%
<i>CHEK2</i>	Yes 25%-30%	No	No	Yes 15%	
<i>PALB2</i>	Yes 40%-60%	Yes 3%-5%	Yes 2%-3%	No	No

<i>PTEN</i>	Yes 40%	No	No	yes 10%	Thyroid cancer 20%; endometrial 20%
<i>RAD51C</i>	Yes 20%	Yes 10%	No	No	No
<i>RAD51D</i>	Yes 10%	Yes 10%	No	No	No
<i>STK11</i>	Yes 40%	No	Yes 10%-30%	Yes 30%	Gastric 30%; Sertoli-Leydig 10%-20%
<i>TP53</i>	Yes 40%	No	Possibly	Possibly	Sarcoma, brain, leukaemia, adrenocortical carcinoma

HBOC, hereditary breast and ovarian cancer syndrome; LBC, lobular breast cancer; PV, pathogenic variant.

Lifetime risk in general 'average risk' population: *breast cancer 11%, †ovarian cancer 1.3%, ‡pancreatic cancer 1.6%, §colon cancer 4%.

